ライフサイエンスコーパス: drug development

1 o SARS-CoV-2 infection and should facilitate drug development.

2 that will inspire future anti-staphylococcal drug development.

3 tiviral attack and holds promise for further drug development.

4 es and are a major target for pharmaceutical drug development.

5 ex (GP) is a promising target for vaccine or drug development.

6 elivery is invaluable for the advancement of drug development.

7 K, have major implications for antimicrobial drug development.

8 veries regarding pathogenesis and innovative drug development.

9 n protein evolution, protein engineering and drug development.

10 reveals a novel target for potent antiviral drug development.

11 effects of targeting ANGPT2 have complicated drug development.

12 ss of managing reactive metabolite issues in drug development.

13 aving the way for a new era of RAMP-targeted drug development.

14 ng the practical utility of microdroplets in drug development.

15 rmacological challenge to anticancer peptide drug development.

16 profiles make excellent starting points for drug development.

17 netic properties appear suitable for further drug development.

18 n-a signature event in the history of modern drug development.

19 represents key mechanistic milestones during drug development.

20 nclature to inform clinical trial design and drug development.

21 be highly robust for routine bioanalysis in drug development.

22 is an AAA+ ATPase, is a promising target for drug development.

23 eptor and provides RET agonist scaffolds for drug development.

24 t this imaging modality could have a role in drug development.

25 and suggest avenues for future research and drug development.

26 T(4)R may be a novel target for prophylactic drug development.

27 be used as a basis for future strategies in drug development.

28 e Mla pathway, which could aid antimicrobial drug development.

29 goal of fundamental biology and therapeutic drug development.

30 resses major obstacles of anti-paramyxovirus drug development.

31 es for asymmetric transformations and chiral drug development.

32 interactions receive little attention during drug development.

33 ty provide a new framework to personalize AF drug development.

34 s chemical probes and as potential leads for drug development.

35 ls as well as expedite and lower the cost of drug development.

36 ssment of pharmacokinetics and biomarkers in drug development.

37 ers is a challenging but essential aspect of drug development.

38 which is a critical target for tuberculosis drug development.

39 facilitate hypothesis generation for future drug development.

40 ty of human genetic variation can facilitate drug development.

41 al gene regulatory network construction, and drug development.

42 g targets are becoming a fundamental tool in drug development.

43 gonists or antagonists of BACH2 function for drug development.

44 ntially targetable gene sets for therapeutic drug development.

45 ibitors, representing an excellent basis for drug development.

46 addition as a potential target for antiviral drug development.

47 mbrane steroid reductases and may facilitate drug development.

48 igases with application in biotechnology and drug development.

49 herapies present an entirely new paradigm in drug development.

50 interaction, showing the potential of SRS in drug development.

51 and models for market reform and sustainable drug development.

52 otential lead compound for future autoimmune drug development.

53 surrogate markers may accelerate early-phase drug development.

54 chanisms of action remain unclear, hampering drug development.

55 and pathways that may offer new targets for drug development.

56 vivo, making PRPF4B a candidate for further drug development.

57 optimising their use is vital for efficient drug development.

58 knowledge that need to be addressed to guide drug development.

59 s a persistent bottleneck in biocatalyst and drug development.

60 ds lead compound development for therapeutic drug development.

61 rimental models used widely for research and drug development.

62 preclinical models tell us much about novel drug development.

63 tem for studying disease pathophysiology and drug development.

64 ioactive mediators and potential targets for drug development.

65 ritizing and selecting the right targets for drug development.

66 lysosome as an underexplored target for new drug development.

67 d utility for rapid diagnostic and antiviral drug development.

68 ppeal as a strategy to exploit in anticancer drug development.

69 tics increases the probability of success in drug development.

70 migratory phenotypes impedes pharmaceutical drug development.

71 le-sparing, making it an attractive tool for drug development.

72 pharmacodynamic (PD) biomarker for clinical drug development.

73 ion that might be exploited for diagnosis or drug development.

74 rposed as therapeutics and provide leads for drug development.

75 therapeutics, may thus find applications in drug development.

76 rning platform for mechanistic discovery and drug development.

77 s providing promising avenues to explore for drug development.

78 dentify efficacious combination therapies in drug development.

79 hogen's respiratory enzymes for tuberculosis drug development.

80 physiology, and highlights opportunities for drug development.

81 resents a target space for anti-tuberculosis drug development.

82 may represent a novel therapeutic target for drug development.

83 of this family make them good candidates for drug development.

84 e to the expectations of modern antimalarial drug development.

85 food allergy and may represent a target for drug development.

86 cells suggest that they could be targets for drug development.

87 ortunities to identify molecular targets for drug development.

88 ile also pointing to tangible strategies for drug development.

89 tion therapies, make BsAbs an active area of drug development.

90 TING pathway and review the current state of drug development.

91 independent activity, a relevant feature for drug development.

92 TMs]) of monoclonal antibodies (mAbs) during drug development.

93 ng the need for novel strategies in epilepsy drug development.

94 estinal (GI) absorption of drugs and in oral drug development.

95 get for the spicy taste sensor and analgesic drug development.

96 derstanding of the underlying mechanisms and drug development.

97 on is a prioritized target for antipsychotic drug development.

98 scaffold possesses promising properties for drug development.

99 4 structures make them important targets for drug development.

100 cation, making nsp10 an important target for drug development.

101 re discussed as well as the impact on future drug development.

102 f known pharmacophores is a key strategy for drug development.

103 synthesis and is a target for antibacterial drug development.

104 tivities can benefit biological research and drug development.

105 , serving as promising targets for antiviral drug development.

106 Such information is required for further drug development.

107 y for cellular protein networks important to drug development.

108 otential applications in cancer research and drug development.

109 tform to guide target validation and cardiac drug development.

110 cs/targets in tissues, which is critical for drug development.

111 terpretation of loss-of-function variants in drug development.

112 stic and offers a strategy for combinatorial drug development.

113 ting the inclusion of comparative studies in drug development.

114 lengthy, conservative, and impede efficient drug development.

115 ical for improving diagnosis, treatment, and drug development.

116 aging are urgently needed for diagnostic and drug development.

117 a potential target of lipid based antiviral drug development.

118 utically responsive biomarkers to streamline drug development.

119 FZD structure provides a basis for anti-FZD drug development.

120 Antibacterial drug development activity rebounded substantially from 2

121 lcineurin cascade is an attractive target in drug development against eukaryotic pathogens.

122 hip study provides a perspective for further drug development against flaviviral infections.

123 ClpXP is an important target for drug development against infectious diseases.

124 which offers an exciting new way to approach drug development against this cancer-enhancing protein.

125 ic details of the enzyme and inform rational drug development against this pernicious virus.

126 molecular glues represents a new modality in drug development, allowing development of therapeutic ag

127 two leading oncologists involved in clinical drug development, an expert in regulatory science and pr

128 rns of MbA accumulation limit its supply for drug development and application.

129 peptidomimetics of interest in the fields of drug development and biomaterials.

130 An open debate with a special focus on drug development and biomedical engineering, big data an

131 kidney injury and remains a major concern in drug development and clinical care.

132 For effective integration into drug development and clinical practice, robust assays wi

133 studies and detail their potential impact on drug development and clinical practices.

134 might have implications for their respective drug development and clinical translation.

135 activation has occurred and could be used in drug development and clinical trials of cancer immunothe

136 rstanding of disease course are critical for drug development and clinical trials.

137 NA transcription from cccDNA, and assist new drug development and disease management.

138 HBV-RNA transcription from cccDNA and assist drug development and disease management.

139 od to predict DDIs while being beneficial to drug development and disease treatment.

140 selection of clinical trial participants for drug development and for timely treatment once an interv

141 st-effective and time-efficient than de novo drug development and has yielded notable successes in ne

142 cal roles in different preclinical stages of drug development and highlight the current challenges in

143 OS has become an integral part of biological drug development and is expected from regulatory agencie

144 iochemistry, with important implications for drug development and medicine.

145 identifying areas for future exploration in drug development and nanotechnology, and discussing futu

146 potential of coagulation models as tools for drug development and personalized medicine.

147 ates how the gut microbiome might be used in drug development and personalized medicine.

148 these molecules can be safely harnessed for drug development and precursors or substrates administer

149 chers and scientists, working in the area of drug development and provide better prognosis.

150 y serve as candidate starting points for CDI drug development and provide new biological tools for st

151 promise as a platform for disease modelling, drug development and regenerative therapies.

152 mRNA sequences is a critical aspect of mRNA drug development and regulatory filing.

153 ents in clinics and in vitro systems used in drug development and screening either do not facilitate

154 ecific biosynthetic gene clusters (BGCs) for drug development and targeting the most prolific produce

155 plications for anti-Alzheimer's research and drug development and the broader field of tauopathies in

156 However, the extraordinarily high costs of drug development and the rare incidence of many fibrotic

157 t deliver a novel target for pharmacological drug development and treatment of bacterial infections.

158 ancer models, thereby improving personalized drug development and treatment planning and ultimately,

159 ve ushered in the modern era of antimalarial drug development, and as a result, numerous lead candida

160 sents difficulties for experimental studies, drug development, and other future research.

161 gh yield and purity for disease research and drug development, and these cells are now gradually ente

162 describe the current state of MAGL inhibitor drug development; and discuss biological factors that co

163 targeted protein degradation is a promising drug development approach for mutant EGFR.

164 Last, we discuss new drug development approaches for pediatric cancers whose

165 The implications for drug development are discussed.

166 refore has great potential in the context of drug development as it can provide an early assessment o

167 pecific sites of N-alkyl drugs is crucial in drug-development as over 50% of the top-selling drugs co

168 TPD is of interest in drug development, as it can address previously inaccessi

169 nts a pressing issue to successfully advance drug development at this receptor and improve upon curre

170 Cyclic peptides are promising scaffolds for drug development, attributable in part to their increase

171 tiple substrates pose a unique challenge for drug development because of an increased potential for o

172 s-known as biased agonism(3)-is important in drug development, because the therapeutic effect may ari

173 dimerization in signal transduction and for drug development, both from a classical ATP-competitive

174 of bioactive compounds is a crucial step for drug development but remains a challenging task despite

175 e quality attributes of ADCs is critical for drug development but remains challenging due to heteroge

176 -LC platform has had a significant impact on drug development by analyzing the HTE samples rapidly wi

177 this study can inform the initial stages of drug development by contributing to a new, diverse and m

178 Biomarkers add value to drug development by improving patient selection criteria

179 Program encourages the use of biomarkers in drug development by instilling confidence and consistenc

180 logy for the treatment of human disease when drug development criteria are incorporated into the desi

181 lishing science-based criteria to accelerate drug development, design safer drugs, and reduce heart r

182 ging importance of biased GPCR activation in drug development, ECD-scFvhFc could be a valuable tool t

183 us essentiality catalog could inform ongoing drug development efforts aimed at intercepting and treat

184 ning and repurposing can enhance traditional drug development efforts and could accelerate the identi

185 e testable hypotheses and grant direction to drug development efforts in this promising area.

186 Therefore, early drug development efforts such as clone selection during

187 d pyrazoles possess a promising scaffold for drug development efforts targeting GS activity in GSDs a

188 easingly recognized as potential targets for drug development efforts, which in the past had focused

189 ing lays the groundwork to streamline future drug development efforts.

190 tant and growing role in cancer research and drug development efforts.

191 t this approach may be promising for further drug development efforts.

192 nstitute the preferred in vitro platform for drug development efforts.

193 hrenia, constitute a major challenge for the drug development enterprise.

194 ation of the 2D-LC HTA platform in a routine drug development environment was achieved for real-world

195 llnesses with the slow pace and high cost of drug development exacerbates this issue.

196 y makes a major contribution to the reported drug development failure rate of 96%.

197 ication is the major cause of clinical phase drug development failure.

198 Capping off an era marred by drug development failures and punctuated by waning inter

199 herapeutic targets for further evaluation in drug development for ADPKD.

200 Drug development for bradykinin-meditated pathologies ha

201 ay enhance and expedite target discovery and drug development for cancer interventions and treatment.

202 s knowledge-based challenges associated with drug development for CNS disorders.

203 we hereby report the utility of the model in drug development for drug candidates that may reduce the

204 n studies and animal models focused on novel drug development for early psychosis.

205 be used to provide new leads for preclinical drug development for mental health and other neurologica

206 There is a need for continued drug development for nonalcoholic steatohepatitis (NASH)

207 s past, it could mark the apex of antibiotic drug development for years to come.

208 the CMV Resistance Working Group of the CMV Drug Development Forum (consisting of scientists, clinic

209 time-efficient practice compared to de novo drug development - has been a promising strategy to over

210 y, while serving to incentivize targeted new drug development, have exacerbated inequitable outcomes

211 unmet needs in AF prevention and treatment, drug developments hitherto have been challenging, and th

212 the priority of some pathways for potential drug development in a cost-effective manner.

213 e challenges intrinsic to histology-agnostic drug development in oncology, including biological, regu

214 t applications across disease prediction and drug development in relation to the COVID-19 pandemic ar

215 ve the potential to be used in antibacterial drug development in strains carrying the NorA efflux pum

216 he series of failures that has characterised drug development in this disease area.

217 to be pharmaceutically relevant targets for drug development in treating the adverse effects of Bic.

218 tial in these sequalae, and thus, to support drug development, in this review, we provide a summary o

219 current state of rapid-acting antidepressant drug development, including NMDA channel blockers, glyci

220 CR4 mutations in WM has facilitated rational drug development, including the development of BTK and C

221 , and our understanding to date has impacted drug development, influenced enzyme design, and deepened

222 concerning pathogenesis-driven discovery and drug development into sharper focus.

223 A current trend in drug development involves the use of high molecular weig

224 Drug development is expensive, attrition rates are high,

225 However, model generation for drug development is still expensive and time-consuming,

226 A major challenge in drug development is the optimization of intestinal absor

227 As a guide to safe drug development, it therefore becomes important to be a

228 Chirality is an important consideration in drug development: it can influence recognition of the in

229 lthough (89)Zr-immuno-PET is a young tool in drug development, its application is rapidly expanding,

230 in studies of basic pharmacology as well as drug development, largely due to the high subtype specif

231 to improve too-often-misleading early-phase drug development methods by incorporating biomarker-base

232 Challenges in drug development of neurological diseases remain mainly

233 ncentrations in rats and support the further drug development of Ramizol as a first-in-class antibiot

234 ughput screening (HTS) research programs for drug development or chemical hazard assessment are desig

235 assess compound efficacy at early stages of drug development or in personalized medicine.

236 reactions result in the early termination of drug development or the withdrawal of drugs from the mar

237 ng may lead to new targets or approaches for drug development or treatment regimens that may affect b

238 Targeted protein degradation is a promising drug development paradigm.

239 s key for a myriad of applications including drug development, peptide design and identification of d

240 tors and establish a mechanistically diverse drug development pipeline are unknown.

241 ncreasing number of biosimilars entering the drug development pipeline as many branded biologics are

242 The classical drug development pipeline necessitates studies using ani

243 s suite of phenotypic assays should ensure a drug development pipeline with diverse MMOA without the

244 hows great potential for revolutionizing the drug development pipeline.

245 rgets has led to new approaches entering the drug development pipeline.

246 sources, they have been widely adopted into drug development pipelines.

247 nal model of pathological anxiety to improve drug development pipelines.

248 novel indications for drugs, bypasses common drug development pitfalls to ultimately deliver therapie

249 creenings that may eventually accelerate the drug development process for GBM.

250 iles are a tool commonly used throughout the drug development process to align interested parties aro

251 At the early stages of the drug development process, thousands of compounds are syn

252 oncept tool that has potential to hasten the drug development process.

253 tients, which resulted in termination of the drug development programme.

254 ed diagnostic accuracy, increased yield from drug development programmes and improved stratification

255 ate the evaluation and prioritization of new drug development programmes and repurposing of trials to

256 (DILI) is a leading cause of termination in drug development programs and removal of drugs from the

257 For drug development programs initiated between 2000 and 200

258 Antibacterial drug development programs initiated in the 1980s and 199

259 Evaluation of data from historic drug development programs showed that target-indication

260 tes that are increasingly seen in failed CNS drug development programs.

261 estigational drugs and the outcomes of these drug development programs.

262 ul PK predictions so that 83% of AstraZeneca drug development projects progress in the clinic with no

263 In the past years, however, drug development research has focused on studying alpha5

264 bolites has received inordinate attention in drug development research.

265 Furthermore, characterizing drug development risk, the probability that a drug will

266 ide a more accurate and unbiased estimate of drug development risk.

267 at least considered for application in most drug development scenarios.

268 g cause of drug attrition at the preclinical drug development stage, the National Center for Toxicolo

269 models are increasingly used for preclinical drug development, strategies to account for the nonhuman

270 orak et al. supports metabolite mimicry as a drug development strategy.

271 potential to produce radical improvement in drug development success rate.

272 lated from reported preclinical and clinical drug development success rates were also close to the a

273 y prediction remains a critical challenge in drug development, synthetic route and chemical process d

274 qually important aspect of modern antifungal drug development takes a balanced look at the problems o

275 but also a pharmacological lead for further drug development targeting cancer.

276 he development of high-throughput assays for drug development targeting this channel.

277 ructure and biochemistry has limited further drug development targeting this receptor.

278 his work also provides a platform for future drug development targeting TRPA1.

279 ental components, and an important source of drug development targets and biomarkers.

280 fied, these drugs could provide insights for drug development targets.

281 risk, identifying high-value biomarkers and drug development targets.

282 Novel drug development, testing and progression to clinical tr

283 itution strategy offers new opportunities in drug development that go beyond the metabolic stabilizat

284 didate target for novel immuno-oncology (IO) drug development that is centered on the use of small mo

285 However, given the accelerating pace of drug development, there is a crucial need for in vivo pr

286 ptor (GCGR) in disease and in pharmaceutical drug development, there is a lack of specific and sensit

287 rug repurposing, precision oncology, and new drug development, through different data partition schem

288 and long-term priorities for antiretroviral drug development to guide industry and other stakeholder

289 The enzyme is therefore a target for drug development to manage these various disorders.

290 cusses current research in novel targets and drug development to overcome these clinical challenges.

291 .S. Food and Drug Administration through the Drug Development Tool Qualification process, focus group

292 ly accepted by pharmaceutical companies as a drug development tool.

293 Thus, directed drug development, toward personalised cancer treatment,

294 tic success highlight the need for continued drug development using improved modeling systems.

295 step, especially in the field of psychiatric drug development which faces a high failure rate.

296 maging (MALDI-MSI) is an established tool in drug development, which enables visualization of drugs a

297 rtunities for integrating these findings and drug development with new multidisciplinary advances to

298 ay 1 focused on the utility of biomarkers in drug development(,) with considerations for seeking regu

299 s approach has evolved in the current era of drug development, with multiple other development pathwa

300 nucleotides represent a promising avenue for drug development, with small interfering RNAs (siRNA) an